// App-Quantinova.ai

CT525 : GDX012U-001 A phase 1, open-label, dose escalation, and dose expansion study to assess the safety, tolerability, and preliminary antileukemic activity of GDX012 in patients with MRD positive AML

Researchers

Presenter

  • Lisa J. Knowles

Principal Investigators

  • Mohsan Malik

  • Oliver Nussebaumer

  • Alice Brown

  • Sandra Van Wetering

  • Michael Koslowski

Medical Centers

  • GammaDelta Therapeutics Limited, London, United Kingdom

Locations

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • Acute myelocytic leukemia

Biomarkers

  • Protein Tyrosine Phosphatase, Receptor Type C

Drug/Treatment

  • Cyclophosphamide

  • Cyclophosphamide Injection

  • fludarabine tablet

Outcome

  • N/A

Study Design

  • Open Label

  • Expansion Study

  • Dose Escalation

  • Cohort

  • First-In-Human

Phase

  • I

Study Id's

  • NCT05001451

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved